Mr. Myers has broad experience in M&A, licensing, litigation and intellectual property, including more than 16 years experience in intellectual property acquisition, enforcement and defense in the biotech and pharmaceutical fields. Mr. Myers joined Corixa in 2004 and served as associate general counsel, intellectual property. In 2005, Corixa was acquired by GlaxoSmithKline, plc., during which time Mr. Myers played a key role in the transition of assets. Mr. Myers also served as senior patent counsel to Pfizer Inc., where his responsibilities included global management of Pfizer's antiviral therapeutic portfolio, as well as patent enforcement and defense in the US, Canada, Asia and Japan. Prior to his in-house work, Mr. Myers served as outside counsel to several Fortune 500 companies. Mr. Myers received an M.S. in Molecular Pharmacology from Thomas Jefferson University in Philadelphia, PA and his J.D. from George Washington University in Washington, DC.
VLST recently relocated its operations within Seattle to a new corporate headquarters at 307 Westlake Avenue North. The new office location provides for expanded laboratory and research facilities.
VLST Corporation is a privately held biotechnology company dedicated to
the streamlined discovery and development of novel therapeutics for the
treatment of inflammatory and autoimmune disorders. The VLST approach
combines novel bioinformatics and cutting-edge proteomics to provide a
rapid and rational approach to identifying new targets for the development
of novel biologic therapies. The VLST discovery platform has primary
applications for the treatment of rheumatoid arthritis, Crohn's disease,
|SOURCE VLST Corporation|
Copyright©2008 PR Newswire.
All rights reserved